Drugs / ZL-85FA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07339748 | Jun 2026 → Jun 2028 expected | neoplasm | Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-85FA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07339748 ↗ |
| Route | Oral | “ZL-85FA tablets 2.5mg, oral, once daily” NCT07339748 ↗ |